{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:26:31Z","timestamp":1789392391143,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tens of millions of people worldwide will develop Alzheimer's disease (AD), and only by intervening early in the preclinical disease can we make a fundamental difference to the rates of late-stage disease where clinical symptoms and societal burden manifest. However, collectively utilizing data, samples, and knowledge amassed by large-scale projects such as the Innovative Medicines Initiative (IMI)-funded European Prevention of Alzheimer's Dementia (EPAD) program will enable the research community to learn, adapt, and implement change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In the current article, we define and discuss the substantial assets of the EPAD project for the scientific community, patient population, and industry, describe the EPAD structure with a focus on how the public and private sector interacted and collaborated within the project, reflect how IMI specifically supported the achievements of the above, and conclude with a view for future.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The EPAD project was a \u20ac64-million investment to facilitate secondary prevention of AD dementia research. The project recruited over 2,000 research participants into the EPAD longitudinal cohort study (LCS) and included over 400 researchers from 39 partners. The EPAD LCS data and biobank are freely available and easily accessible <jats:italic>via<\/jats:italic> the Alzheimer's Disease Data Initiative's (ADDI) AD Workbench platform and the University of Edinburgh's Sample Access Committee. The trial delivery network established within the EPAD program is being incorporated into the truly global offering from the Global Alzheimer's Platform (GAP) for trial delivery, and the almost 100 early-career researchers who were part of the EPAD Academy will take forward their experience and learning from EPAD to the next stage of their careers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Through GAP, IMI-Neuronet, and follow-on funding from the Alzheimer's Association for the data and sample access systems, the EPAD assets will be maintained and, as and when sponsors seek a new platform trial to be established, the learnings from EPAD will ensure that this can be developed to be even more successful than this first pan-European attempt.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1051543","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T06:55:20Z","timestamp":1669100120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia"],"prefix":"10.3389","volume":"13","author":[{"given":"Stina","family":"Saunders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H. S.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Birck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge van der","family":"Geyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.trci.2018.03.005","article-title":"Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease","volume":"4","author":"Yilmaz","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e021017","DOI":"10.1136\/bmjopen-2017-021017","article-title":"European prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol","volume":"8","author":"Solomon","year":"2019","journal-title":"BMJ Open."},{"key":"B5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","article-title":"Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project","volume":"3","author":"Ritchie","year":"2016","journal-title":"Lancet Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-019-0576-y","article-title":"Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings","volume":"12","author":"Vermunt","year":"2020","journal-title":"Alzheimers Res Therapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/1471301218789307","article-title":"Research participants as collaborators: Background, experience and policies from the PREVENT Dementia and EPAD programmes","volume":"17","author":"Gregory","year":"2018","journal-title":"Dementia."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975759.017","article-title":"The European Prevention of Alzheimer's disease program: a public\u2013private partnership to facilitate the secondary prevention of Alzheimer's Disease Dementia","volume-title":"Alzheimer's Disease Drug Development: Research and Development Ecosystem","author":"Ritchie","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14283\/jpad.2019.46","article-title":"The European Prevention of Alzheimer's Dementia (EPAD) longitudinal cohort study: baseline data release V500.0","volume":"7","author":"Ritchie","year":"2020","journal-title":"J Prev Alzheimers Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/alz.12292","article-title":"Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort","volume":"17","author":"Ingala","year":"2021","journal-title":"Alzheimers Demen."},{"key":"B11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JAD-190222","article-title":"Associations between multimorbidity and cerebrospinal fluid amyloid: a cross-sectional analysis of the european prevention of Alzheimer's Dementia (EPAD) V500.0 Cohort","volume":"71","author":"Stirland","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JAD-200514","article-title":"Cognitive dispersion is not associated with cerebrospinal fluid biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort","volume":"78","author":"Watermeyer","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3233\/JAD-191108","article-title":"Cognitive functions as predictors of Alzheimer's disease biomarker status in the European Prevention of Alzheimer's dementia cohort","volume":"74","author":"Terrera","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"fcac257","DOI":"10.1093\/braincomms\/fcac257","article-title":"Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults","volume":"4","author":"Blackman","year":"2022","journal-title":"Brain Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"676168","DOI":"10.3389\/fdata.2021.676168","article-title":"Disease modelling of cognitive outcomes and biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort","volume":"4","author":"Howlett","year":"2021","journal-title":"Front Big Data."},{"key":"B16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jalz.2018.02.010","article-title":"European Prevention of Alzheimer's Dementia Registry: recruitment and prescreening approach for a longitudinal cohort and prevention trials","volume":"14","author":"Vermunt","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40900-020-00236-z","article-title":"Involving research participants in a pan-European research initiative: the EPAD participant panel experience","volume":"6","author":"Gregory","year":"2020","journal-title":"Res Involv Engagem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.ebiom.2022.104241","article-title":"Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)","volume":"83","author":"Saunders","year":"2022","journal-title":"eBioMedicine."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1111\/1467-9566.13374","article-title":"Lived time and the affordances of clinical research participation","volume":"43","author":"Brenman","year":"2021","journal-title":"Sociol Health Illness."},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13195-020-00711-5","article-title":"Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study","volume":"12","author":"Calvin","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"fcac150","DOI":"10.1093\/braincomms\/fcac150","article-title":"Regional associations of white matter hyperintensities and early cortical amyloid pathology","volume":"4","author":"Lorenzini","year":"2022","journal-title":"Brain Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12021","DOI":"10.1002\/dad2.12021","article-title":"The influence of diversity on the measurement of functional impairment: an international validation of the Amsterdam IADL Questionnaire in eight countries","volume":"12","author":"Dubbelman","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/01622439211007196","article-title":"\u201cready for what?\u201d: timing and speculation in Alzheimer's disease drug development","volume":"47","author":"Brenman","year":"2021","journal-title":"Sci Technol Hum Values."},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12877-021-02693-x","article-title":"Assessing and disclosing test results for \u2018mild cognitive impairment': the perspective of old age psychiatrists in Scotland","volume":"22","author":"Saunders","year":"","journal-title":"BMC Geriatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","article-title":"Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study","volume":"16","author":"Lopes Alves","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","article-title":"AMYPAD diagnostic and patient management study: rationale and design","volume":"15","author":"Frisoni","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15821.","article-title":"Self-reported diabetes is associated with allocentric spatial processing in the european prevention of alzheimer's dementia longitudinal cohort study","author":"Gregory","year":"2022","journal-title":"Eur J Neurosci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13195-017-0312-4","article-title":"The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease","volume":"9","author":"Ritchie","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/alz.12132","article-title":"Precision prevention of Alzheimer's and other dementias: anticipating future needs in the control of risk factors and implementation of disease-modifying therapies","volume":"16","author":"Frisoni","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.14283\/jpad.2021.63","article-title":"The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland","volume":"2","author":"Ritchie","year":"2021","journal-title":"J Prev Alzheimers Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(21)00364-0","article-title":"New global initiative to Tackle Alzheimer's disease","volume":"397","author":"Siva","year":"2021","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13195-021-00827-2","article-title":"Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services\u2014part 1 of 6","volume":"13","author":"Altomare","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13195-021-00895-4","article-title":"Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6","volume":"13","author":"Ranson","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13195-021-00885-6","article-title":"Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services-part 6 of 6","volume":"13","author":"Milne","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13195-021-00875-8","article-title":"Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6","volume":"13","author":"Solomon","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13195-021-00840-5","article-title":"Dementia risk communication. A user manual for Brain Health Services-part 3 of 6","volume":"13","author":"Visser","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-021-00844-1","article-title":"Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6","volume":"13","author":"Brioschi Guevara","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.14283\/jpad.2021.21","article-title":"Platform trials to expedite drug development in Alzheimer's disease: a report from the EU\/US CTAD Task Force","volume":"8","author":"Aisen","year":"2021","journal-title":"J Prev Alzheimers Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1051543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T06:55:23Z","timestamp":1669100123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1051543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":39,"alternative-id":["10.3389\/fneur.2022.1051543"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1051543","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"article-number":"1051543"}}